



**NIDAN LABORATORIES
AND HEALTHCARE LTD**

ERSTWHILE NIDAN LABROTARIES & HEALTHCARE PVT LTD

CIN No. : U33111MH2000PLC129883

19.45707, 72.81031

Swapnashilp, Behind Aarti Apt. Vartak Road,
Virar (West), 401303, Mumbai, India.

Date: 25th May, 2022

To,
National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex, Bandra (East),
Mumbai 400 051.

Subject: Audited Financial Results of Nidan Laboratories and Healthcare Limited for the year ended 31st March, 2022.

Reference: NSE Symbol - NIDAN

Madam / Sir,


This is to inform you that pursuant to Regulation 33 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 and other applicable provisions, the Board of Directors of the Company at its meeting held today have approved the Audited Financial Results and Auditors Report of the Company for the financial year ended 31st March, 2022

In view of the above, we hereby enclose the following:

1. Audited Financial Results in respect of Nidan Laboratories and Healthcare Limited for the yearended 31st March, 2022.
2. Statutory Auditor's Report on Audited financial results of Nidan Laboratories and Healthcare Limited for the year ended 31st March, 2022.
3. A declaration with respect to Audit Report with unmodified opinion to the audited financial results.

This is for your information and records.

For Nidan Laboratories and Healthcare Limited


Akshay Joshi

Company Secretary & Compliance Officer
ACS:34724



NIDAN LABORATORIES AND HEALTHCARE LTD

ERSTWHILE NIDAN LABROTARIES & HEALTHCARE PVT LTD

CIN No. : U33111MH2000PLC129883

19.45707, 72.81031

Swapnashilp, Behind Aarti Apt. Vartak Road,
Virar (West), 401303, Mumbai, India.

Date: 25th May, 2022

To,
National Stock Exchange of India Limited
Exchange Plaza,
Bandra Kurla Complex, Bandra (East),
Mumbai 400 051.

Subject: Declaration w.r.t Audit Report with unmodified opinion on the Audited Financial results for the financial year ended 31st March, 2022.


Reference: NSE Symbol - NIDAN

Madam / Sir,

Pursuant to Regulation 33(3)(d) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Company hereby declares that M/s R. K. Chapawat & Co., Chartered Accountants, (Membership No. 37720) the Statutory Auditors of the Company have issued their Audit Report on the Audited Financials Results of the Company for the financial year ended 31st March, 2022 with unmodified opinion.

This is for your information and records.

For Nidan Laboratories and Healthcare Limited


Tejal Anil Jayakar
Director
DIN: 07984686



R. K. GHAPAWAT & CO.

CHARTERED ACCOUNTANTS

Office : 122, Shripal Shopping Center, Near Petrol Pump, Agashi Road, Virar (West) Dist - Palghar : 401303.
Contact : +91-9323791318 / 0250-2513406, **E-mail :** ravindra_chapawat@rediffmail.com

Independent Auditor's Report on the Half Yearly and Year to date Audited Financial Results of the Company Pursuant to the Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended

M/S. NIDAN LABORATORIES AND HEALTHCARE LIMITED

Report on the audit of the financial statements

Opinion

We have audited the accompanying statement of half yearly and year to date financial results of NIDAN LABORATORIES AND HEALTHCARE LIMITED ("the Company") for the half year ended March 31, 2022 and for the year ended March 31st, 2022 ("Statement"), attached herewith, being submitted by the company pursuant to the requirement of Regulation 33 and 52 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

In our opinion and to the best of our information and according to the explanations given to us, the Statement:


1. is presented in accordance with the requirements of the Listing Regulations in this regard; and
2. gives a true and fair view in conformity with the applicable accounting standards and other accounting principles generally accepted in India, of the net profit and other financial information of the Company for the half year ended March 31, 2022 and for the year ended March 31, 2022.

Basis for opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified Under section 143(10) of the Companies Act, 2013, as amended ("the Act"). Our Responsibilities under those Standards are further described in the "Auditor's Responsibilities for the Audit of the Financial Results" section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Act and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our opinion.

Management's Responsibility for the Financial Results

The Statement has been prepared on the basis of the Annual Financial Statements. The Board of Directors of the Company are responsible for the preparation and presentation of the Statement that gives a true and fair view of the net profit and other financial information of the Company in



accordance with the applicable accounting standards prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 and 52 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and the design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the standalone financial statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

The Board of Directors are responsible for overseeing the Company's financial reporting process.

Auditor's Responsibilities for the Audit of the Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole is free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery intentional omissions, misrepresentations, or the override of internal control.
- Obtain an understanding of internal financial controls **ANNEXURE "A"** relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Act, we are also responsible for expressing our opinion on whether the Company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- Conclude on the appropriateness of the Board of Directors' use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention



in our auditor's report to their related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.

- Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.


We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

The Statement includes the results for the half year ended March 31, 2022 being the balancing figure between the audited figures in respect of the full financial year ended March 31, 2022 and the published unaudited year-to-date figures up to the 1st half year of the current financial year, which were subjected to a limited review by us, as required under the Listing Regulations.

For **R. K CHAPAWAT & CO.**

Chartered Accountants
Firm Reg. NO. W101708



RAVINDRA CHAPAWAT
PARTNER

Membership No.: 037720

UDIN:- **22037720AJOMSK2853**

DATE: 25/05/2022



NIDAN LABORATORIES AND HEALTHCARE LIMITED

CIN - U33111MH2000PLC129883

Regd Office: SY No. 294/A H. No. 18, Swapnshilpa, Behind Aarti Apartment, Vartak Road, Virar (w), 401303

Tel No. +91 8975610000, E-Mail:cs@nidanhealthcare.co.in, Website: www.nidanhealthcare.co.in

Statement of Audited Financial Results for the Half and year Ended on 31st March 2022

	Particulars	Half Year ended (Rs in lakhs)		Year Ended (Rs in lakhs)	
		31-Mar-22	30-Sep-21	31-Mar-22	31-Mar-21
		Audited	Unaudited	Audited	Audited
1	Income				
	a) Revenue from Operations	1,313.80	1652.21	2,966.01	2,037.75
	b) Other Income	38.99	1.23	40.22	106.13
	Total Income (a+b)	1,352.80	1,653.44	3,006.24	2,143.88
2	Expenses				
	a) Cost of Materials Consumed			-	-
	b) Purchase of Stock -in-trade	118.38	201.54	319.92	222.94
	c) Changes in inventories of Finished Goods, Work in Progress and Stock-in- Trade	3.70	-14.7	(11.00)	(2.00)
	d) Employee benefit expenses	210.68	156.84	367.52	288.85
	e) Finance Costs	94.61	171.87	266.48	346.15
	f) Depreciation and Amortization expenses	87.14	175.94	263.08	318.44
	g) Other Expenses	618.97	729.22	1,348.19	639.26
	Total Expenses (a to g)	1,133.49	1,420.71	2,554.20	1,813.65
3	Profit / (Loss) before tax	219.31	232.73	452.04	330.23
4	Tax Expenses				
	a) Current Tax	79.64	52.36	132.00	99.99
	b) Deferred Tax Asset/Liability	(20.29)	-	(20.29)	-
	c) Tax of earlier year	74.04	-	74.04	-
	Total tax expenses	133.39	52.36	185.75	99.99
5	Profit/(loss) for the period	85.92	180.37	266.29	230.24
6	Other Comprehensive Income (OCI)				
	A. (i) Items that will not be			-	-
	(ii) Income tax relating to Items that will not be reclassified to profit or loss			-	-
	B. (i) Items that will be reclassified to profit or loss			-	-
	(ii) Income tax relating to Items that will be reclassified to profit			-	-
	Total other Comprehensive Income (Net of tax)			-	-
7	Total Comprehensive Income for the period	85.92	180.37	266.29	230.24
8	Paid-up equity share capital Face value of Rs 10/- per	1,390.00	990	1,390.00	990.00
9	Earnings Per Share (not annualised)				
	a) Basic EPS	0.62	1.82	2.32	2.33
	b) Diluted EPS	0.62	1.82	2.32	2.33

Notes:

1) The above financial results have been reviewed by Audit Committee and approved by Board of Directors in their respective meetings held on 25th May, 2022 and have been audited by the Statutory Auditors of the Company. The Statutory Auditors have expressed an unmodified opinion on the aforesaid results.

exempted from the compulsory requirement of adoption of Ind AS. As the company is covered under exempted from the compulsory requirement of adoption of Ind AS, the company has not adopted Ind AS.

3) The Company does not have different segments and hence segment wise reporting is not applicable to the Company.

4) The figures of the previous period/year have been regrouped/rearranged wherever considered necessary to make them comparable



For and on behalf of Board of Directors
NIDAN LABORATORIES AND HEALTHCARE LIMITED

Tejal Anil Jayakar
Executive Director
DIN:07984686

PLACE : VIRAR
DATE : 25TH MAY 2022

NIDAN LABORATORIES AND HEALTHCARE LTD
Statement of Assets & Liabilities for the year ended 31st march 2022

Rs in lakhs

	Particulars	Note No.	As at March 31, 2022 (Audited)	As at March 31, 2021 (Audited)
I	Equity & Liabilities			
	1. Shareholders' funds			
	Equity Share Capital	3	1,390.00	990.00
	Reserves and Surplus	4	5,199.89	343.10
			6,589.89	1,333.10
	2. Non - Current Liabilities			
	Long - Term Borrowings	5	941.74	1,415.65
	Other Long term liabilities	6	34.04	6.54
	Long Term Provisions	7	3.93	-
			979.72	1,422.19
	3. Current Liabilities			
	Short - Term Borrowings	8	987.73	2,388.91
	Trade Payables			
	(i) Total outstanding due of micro enterprises and small enterprises; and	9	-	-
	(ii) Total outstanding dues of creditors other than micro enterprises and small	10	114.87	128.90
	Other Current Liabilities	11	47.08	30.81
	Short - Term Provisions		128.62	70.12
			1,278.30	2,618.73
	TOTAL		8,847.90	5,374.02
II	Assets			
	1. Non - Current Assets			
	Property Plant & equipment and Intangible Assets			
	(i) Tangible Assets	12	2,427.35	2,014.16
	(ii) Intangible Asset		-	-
	Non-Current Investments	13	2,953.90	27.01
	Long - Term Loans and Advances	14	818.00	828.00
	Deferred Tax Asset (Net)	15	45.37	25.07
	Other Non Current Assets	16	175.42	187.97
			6,420.04	3,082.22
	2. Current Assets			
	Inventories	17	21.58	10.58
	Trade Receivables	18	536.17	543.19
	Cash and Cash Equivalents	19	810.14	729.67
	Bank balances other than cash and cash equivalents		-	-
	Short - Term Loans and Advances	20	55.60	-
	Other Current Assets	21	1,004.37	1,008.36
			2,427.86	2,291.80
	TOTAL		8,847.90	5,374.02

For and on behalf of Board of Directors
Nidan Laboratories And Healthcare Limited

Tejal Anil Jayakar
Executive Director
DIN:07984686



DATE : 25TH MAY 2022
PLACE: VIRAR

Nidan Laboratories And Healthcare Limited
Statement of Cash flow for the year ended 31st March 2022

Rs in lakhs

Particulars	For the year ended March 31, 2022	For the year ended March 31, 2021
A - CASH FLOW FROM OPERATING ACTIVITIES		
Restated Profit Before Tax	452.04	330.23
Add/ (less) Adjustment for:		
Interest Income	(0.53)	-
Interest Expenses	243.53	336.44
Depreciation	263.08	318.44
Sundry Balance Written back	(23.63)	-
(Gain)/loss on disposal of property, plant and equipment	(28.90)	-
Operating Profit Before Working Capital Changes	905.59	985.12
Add/ (less): Adjustments for Changes in working capital:		
(Increase) / decrease in Trade Receivable	7.02	-
(Increase)/ decrease in Other Current Assets	3.98	18.25
(Increase) / decrease in Short Term Loans and Advances	(55.60)	(726.54)
(Increase) / decrease in Other Non current assets	12.55	-
(Increase) / decrease in Inventories	(11.00)	(2.00)
Increase / (decrease) in Trade payables	(14.03)	-
Increase / (decrease) in Long term liability	27.50	-
Increase / (decrease) in Other current Liability	16.28	152.37
Increase / (decrease) in Short Term Provision	2.70	7.33
Increase / (decrease) in Long term Provisions	3.93	-
Cash Generated from Operations	898.92	434.53
Add/ (less) : Direct taxes paid (net of refund received)	(116.17)	-
Net Cash inflow from Operating Activities	782.76	434.53
B - CASH FLOW FROM INVESTING ACTIVITIES		
Acquisition of property, plant and equipment / intangible assets	(707.44)	(322.45)
Proceeds from Issue of shares (net)	4,990.50	-
Proceeds from sale of property, plant and equipment	59.62	-
(Purchase)/Sale of Investments	(2,926.89)	-
Interest received	0.53	-
Net cash inflow/(outflow) from investing activities	1,416	(322)
C - CASH FLOW FROM FINANCING ACTIVITIES		
Proceeds / (repayment) of borrowings (net)	(1,875.08)	214.72
Interest Expenses	(243.53)	(336.44)
Net Cash inflow/(outflow) flow from Financing Activities	(2,119)	(122)
Net (Decrease) / Increase in Cash and Cash Equivalents (A+B+C)	80.46	(9.63)
Add: Cash and Cash Equivalents at the beginning of the year	729.67	739.31
Cash and Cash Equivalents at the end of the period/year	810.14	729.67
Notes :		
Cash and Cash Equivalents at the end of the year consists of cash in hand and balances with banks are as follows :		
Particulars	As at March 31, 2022	As at March 31, 2021
Cash on hand	770.28	665.79
Balances with bank	39.85	63.88
Cash and Cash Equivalents	810.14	729.67

For and on behalf of the Board of Directors
Nidan Laboratories And Healthcare Limited

Tejal Jaykar
Director
DIN: 07984686



DATE : 25TH MAY 2022
PLACE : VIRAR

NIDAN LABORATORIES AND HEALTHCARE LIMITED

CIN - U33111MH2000PLC129883

Regd Office: SY No. 294/A H. No. 18, Swapnshilpa, Behind Aarti Apartment,

Vartak Road, Virar (w), 401303

Tel No. +91 8975610000; E-Mail:cs@nidanhealthcare.co.in, Website: www.nidanhealthcare.co.in

STATEMENT OF STANDALONE FINANCIAL RESULTS FOR THE HALF AND YEAR ENDED 31ST MARCH 2022.

S.No.	Particulars	Half Year Ended 31st March 2022	Half Year Ended 30th Sept 2022	YEAR ended 31st March, 2022	YEAR ended 31st March, 2021
		(Audited)	(Unaudited)	(Audited)	(Audited)
1	TOTAL INCOME FROM OPERATIONS	1,352.80	1,653.44	3006.24	2,143.88
2	Net Profit/(Loss) for the period (before tax, exceptional and/or extraordinary items)	219.31	232.73	452.04	330.23
3	Net Profit/(Loss) for the period before tax (after exceptional and/or extraordinary items)	219.31	232.73	452.04	330.23
4	Net Profit/(Loss) for the period after tax (after exceptional and/or extraordinary items)	85.92	180.37	266.29	230.24
5	Total Comprehensive income for the period [comprising Profit/(Loss) for the period (after tax) and other comprehensive Income (after tax)	85.92	180.37	266.29	230.24
6	Equity Share Capital	1,390.00	990.00	1390	990.00
7	Reserves (exluding revaluation reserve) as shown in the audited balance sheet of the previous year	4,676.42	523.47	5199.89	343.10
8	Earnings Per Share (of Rs 10/-each) (for continuing and discontinued operations)				
	Basic	0.62	1.82	2.32	2.33
	Diluted	0.62	1.82	2.32	2.33
1) The above is an extract of the detailed format of Annual Financial Results to filed with National Stock Exchange Limited under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Financial Results are available on the Stock Exchange websites (www.nseindia.com/) and Company's website : www.nidanhealthcare.co.in					

For and on behalf of Board of Directors

NIDAN LABORATORIES AND HEALTHCARE LIMITED



Tejal Anil Jayakar

Executive Director

DIN:07984686

DATE : 25-05-2022

PLACE : VIRAR